The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination
Adult
Aged, 80 and over
Male
Herpesvirus 3, Human
Adolescent
Incidence
Age Factors
Infant
Herpesvirus Vaccines
Middle Aged
Herpes Zoster
3. Good health
Chickenpox Vaccine
Hospitalization
03 medical and health sciences
Chickenpox
0302 clinical medicine
Child, Preschool
Humans
Female
Child
Aged
Netherlands
DOI:
10.1016/j.vaccine.2006.02.017
Publication Date:
2006-02-25T07:16:10Z
AUTHORS (7)
ABSTRACT
We studied the epidemiology of varicella (chickenpox) and herpes zoster (shingles) in The Netherlands to assess the desirability to implement routine varicella zoster virus vaccination in The Netherlands. Data on seroprevalence of varicella zoster virus in the general population (1995-1996), consultations of general practitioners for varicella (2000-2002) and herpes zoster (1998-2001) and hospital admissions due to varicella (1994-2001) and herpes zoster (1994-2001) in The Netherlands were analysed. The seropositivity increased sharply with age from 18.4% for both 0- and 1-year-olds, to 48.9%, 59.0%, 75.7% and 93.0% for 2-, 3-, 4- and 5-year-olds, respectively, and varied between 97.5% and 100% for older age groups. The average annual incidence of GP-consultations amounted to 253.5 and 325.0 per 100,000 for varicella and herpes zoster, respectively. The incidence of hospital admission due to varicella and herpes zoster was 1.3 (2.3 including side diagnosis) and 2.7 (5.8) per 100,000, respectively. Whilst for varicella, the incidence of GP-consultations and hospital admissions were highest in childhood, for herpes zoster, these were highest in elderly. Insight into epidemiology of varicella zoster is needed for the assessment of the desirability of introduction of routine varicella zoster vaccination.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (27)
CITATIONS (108)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....